FLSM
RVMD icon

Frazier Life Sciences Management’s Revolution Medicines RVMD Stock Holding History

Frazier Life Sciences Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-675,686
Closed -$65.7M – 44
2026
Q1 		$65.7M Sell
675,686
-121,769
-15% -$12.3M 1.69% 15
2025
Q4 		$63.5M Sell
797,455
-200,000
-20% -$13.1M 1.71% 15
2025
Q3 		$46.6M Hold
997,455
– – 1.4% 18
2025
Q2 		$36.7M Hold
997,455
– – 1.47% 16
2025
Q1 		$35.3M Hold
997,455
– – 1.61% 16
2024
Q4 		$43.6M Hold
997,455
– – 1.81% 15
2024
Q3 		$45.2M Hold
997,455
– – 1.81% 17
2024
Q2 		$38.7M Hold
997,455
– – 1.81% 16
2024
Q1 		$32.1M Hold
997,455
– – 1.36% 24
2023
Q4 		$28.6M Hold
997,455
– – 1.53% 17
2023
Q3 		$27.6M Buy
997,455
+142,971
+17% +$4.24M 1.83% 17
2023
Q2 		$22.9M Hold
854,484
– – 1.37% 18
2023
Q1 		$18.5M Buy
+854,484
New +$21M 1.34% 21

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Frazier Life Sciences Management's RVMD Position: Q2 2026 in Review

Frazier Life Sciences Management sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 675,686 shares — an estimated $65.7M sold.

Frazier Life Sciences Management first reported a position in RVMD in Q1 2023 and held it in 13 quarters. The position peaked at $65.7M in Q1 2026. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Frazier Life Sciences Management reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Frazier Life Sciences Management sold 675,686 Revolution Medicines shares in Q2 2026, an estimated $65.7M.
  • Frazier Life Sciences Management first reported a position in Revolution Medicines in Q1 2023 and held it in 13 quarters.
  • Frazier Life Sciences Management's Revolution Medicines position peaked at $65.7M in Q1 2026.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.